Uptake and efficacy of trimetrexate (TMQ, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline), a non-classical antifolate in methotrexate-resistant leukemia cells in vitro
- 15 May 1984
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 33 (10), 1697-1699
- https://doi.org/10.1016/0006-2952(84)90298-3
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Correlates of folate analog transport, pharmacokinetics and selective antitumor actionPharmacology & Therapeutics, 1980
- DDMP (2,4-diamino-5-(3′,4′-dichlorophenyl)-methylpyrimidine)Cancer Treatment Reviews, 1980
- 2,4-Diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline (TMQ), a potent non-classical folate antagonist inhibitor—IBiochemical Pharmacology, 1979
- A rapid, radiochemical-ligand binding assay for methotrexateAnalytical Biochemistry, 1976
- ACTIVE-SITE DIRECTED IRREVERSIBLE INHIBITORS OF DIHYDROFOLATE REDUCTASEAnnals of the New York Academy of Sciences, 1971
- Transport Energetics of the Folic Acid Analogue, Methotrexate, in L1210 Leukemia CellsPublished by Elsevier ,1969